en
Scientific article
English

Potent inhibition of HIV-1 by TRIM5-cyclophilin fusion proteins engineered from human components

Published inThe Journal of clinical investigation, vol. 119, no. 10, p. 3035-3047
Publication date2009
Abstract

New World monkeys of the genus Aotus synthesize a fusion protein (AoT5Cyp) containing tripartite motif-containing 5 (TRIM5) and cyclophilin A (CypA) that potently blocks HIV-1 infection. We attempted to generate a human HIV-1 inhibitor modeled after AoT5Cyp, by fusing human CypA to human TRIM5 (hT5Cyp). Of 13 constructs, 3 showed substantial HIV-1-inhibitory activity when expressed in human cell lines. This activity required capsid binding by CypA and correlated with CypA linkage to the TRIM5a capsid-specificity determinant and the ability to form cytoplasmic bodies. CXCR4- and CCR5-tropic HIV-1 clones and primary isolates were inhibited from infecting multiple human macrophage and T cell lines and primary cells by hT5Cyp, as were HIV-2ROD, SIVAGMtan, FIVPET, and a circulating HIV-1 isolate previously reported to be AoT5Cyp resistant. The anti-HIV-1 activity of hT5Cyp was surprisingly more effective than that of the well-characterized rhesus TRIM5alpha, especially in T cells. hT5Cyp also blocked HIV-1 infection of primary CD4+ T cells and macrophages and conferred a survival advantage to these cells without disrupting their function. Extensive attempts to elicit HIV-1 resistance to hT5Cyp were unsuccessful. Finally, Rag2-/-gammac-/- mice were engrafted with human CD4+ T cells that had been transduced by optimized lentiviral vectors bearing hT5Cyp. Upon challenge with HIV-1, these mice showed decreased viremia and productive infection in lymphoid organs and preserved numbers of human CD4+ T cells. We conclude that hT5Cyp is an extraordinarily robust inhibitor of HIV-1 replication and a promising anti-HIV-1 gene therapy candidate.

Keywords
  • Adoptive Transfer
  • Amino Acid Sequence
  • Animals
  • Anti-HIV Agents/*metabolism
  • Aotidae
  • CD4-Positive T-Lymphocytes/cytology/immunology
  • Carrier Proteins/genetics/*metabolism
  • Cell Line
  • Cyclophilin A/genetics/*metabolism
  • DNA-Binding Proteins/genetics/metabolism
  • HIV-1/*metabolism
  • Humans
  • Mice
  • Mice, Knockout
  • Models, Molecular
  • Molecular Sequence Data
  • Protein Conformation
  • Protein Engineering
  • Recombinant Fusion Proteins/genetics/*metabolism
Citation (ISO format)
NEAGU, Martha Raluca et al. Potent inhibition of HIV-1 by TRIM5-cyclophilin fusion proteins engineered from human components. In: The Journal of clinical investigation, 2009, vol. 119, n° 10, p. 3035–3047. doi: 10.1172/JCI39354
Main files (1)
Article
accessLevelRestricted
Identifiers
ISSN of the journal0021-9738
547views
0downloads

Technical informations

Creation04/23/2012 1:24:35 PM
First validation04/23/2012 1:24:35 PM
Update time03/14/2023 5:26:27 PM
Status update03/14/2023 5:26:27 PM
Last indexation02/12/2024 8:02:28 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack